HR Execs on the Move

Bioveris Corporation

www.bioveris.com

 
BioVeris Corporation (BioVeris) is a global healthcare and biosecurity company developing technologies in diagnostics and vaccinology. It develops, manufactures and markets its M-SERIES family of products, which can serve as a platform for diagnostic
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

Reflex Photonics

Reflex Photonics Inc. is a Sherbrooke, QC-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Medallion Laboratories

Medallion Laboratories is a Minneapolis, MN-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

StageBio

StageBio serves preclinical histology, pathology and specimen archiving clients in the biopharmaceutical, medical device and contract research industries.

Metacrine

We are a clinical-stage biopharmaceutical company focused on discovering and developing best-in-class therapies for patients with liver and gastrointestinal, or GI, diseases. Since our founding in 2014, we have invested in building a foundation of chemistry and biology expertise to drive innovative drug discovery and development. We believe these internal capabilities allow us to gain insights into disease targets and mechanisms and more quickly and purposefully design therapies with characteristics that we view as key to safety and efficacy. With this systematic approach, we have designed novel, proprietary farnesoid X receptor (FXR) clinical product candidates arising from a unique chemical scaffold with the potential to be best-in-class for non-alcoholic steatohepatitis, or NASH, and first- in-class for Inflammatory Bowel Disease, or IBD. In addition to our FXR program, we have continued to invest in drug discovery on other therapeutic targets that have effects on inflammation and/or fibrosis for which we believe we could develop proprietary small molecule therapies.

Wheeler Bio

A disruptive new biopharmaceutical CDMO, we are pushing the boundaries of biomanufacturing and solving an outdated industry bottleneck with a unique partnering model. By bringing together biologics drug innovators, discovery CROs, and CDMOs, we are accelerating the translation of therapeutic innovation to clinical impact.